ANTICOAGULATION IN HYPERTROPHIC CARDIOMYOPATHY AND ATRIAL FIBRILLATION: A SINGLE-CENTRE EXPERIENCE.
Anno:
2025
Rationale and aim Based on latest European guidelines, all patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF) should receive anticoagulant therapy irrespective of their thrombotic risk measured by CHA2DS2-VA score (CHA2DS2-VASc score before 2024 guidelines). The aim of our study was to assess the implementation and type of…